Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.

PMID:
21984487
2.

Adjuvant chemotherapy in luminal breast cancers.

Lim E, Winer EP.

Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Review.

PMID:
22015279
3.

Pathological work up of the primary tumor: getting the proper information out of it.

Viale G.

Breast. 2011 Oct;20 Suppl 3:S82-6. doi: 10.1016/S0960-9776(11)70300-9. Review.

PMID:
22015299
4.

Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.

Cadoo KA, Fornier MN, Morris PG.

Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21. Review.

5.

The natural history of hormone receptor-positive breast cancer.

Lim E, Metzger-Filho O, Winer EP.

Oncology (Williston Park). 2012 Aug;26(8):688-94, 696. Review.

6.

FOXP1 and estrogen signaling in breast cancer.

Ijichi N, Ikeda K, Horie-Inoue K, Inoue S.

Vitam Horm. 2013;93:203-12. doi: 10.1016/B978-0-12-416673-8.00006-X. Review.

PMID:
23810008
7.

The effects of under 6 hours of formalin fixation on hormone receptor and HER2 expression in invasive breast cancer: a systematic review.

Kalkman S, Barentsz MW, van Diest PJ.

Am J Clin Pathol. 2014 Jul;142(1):16-22. doi: 10.1309/AJCP96YDQSTYBXWU. Review.

PMID:
24926080
8.

Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.

Lindet C, Révillion F, Lhotellier V, Hornez L, Peyrat JP, Bonneterre J.

Int J Biol Markers. 2012 Jul 19;27(2):e111-7. doi: 10.5301/JBM.2012.9198. Review.

PMID:
22505232
9.

Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis.

Li S, Yang X, Zhang Y, Fan L, Zhang F, Chen L, Zhou Y, Chen X, Jiang J.

Breast Cancer Res Treat. 2012 Sep;135(2):325-34. doi: 10.1007/s10549-012-2063-z. Epub 2012 Apr 22. Review.

PMID:
22527109
10.

Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis.

Shou J, Lai Y, Xu J, Huang J.

Breast. 2016 Jun;27:35-43. doi: 10.1016/j.breast.2016.02.009. Epub 2016 Mar 21. Review.

PMID:
27212698
11.

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E.

J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319. Epub 2013 Nov 22. Review.

PMID:
24273215
12.

Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis.

Petrelli F, Barni S.

Med Oncol. 2012 Dec;29(4):2586-93. doi: 10.1007/s12032-012-0201-4. Epub 2012 Mar 14. Review.

PMID:
22415399
13.

Indications for prognostic gene expression profiling in early breast cancer.

Cobain EF, Hayes DF.

Curr Treat Options Oncol. 2015 May;16(5):23. doi: 10.1007/s11864-015-0340-x. Review.

PMID:
25929335
14.

[Gene expression analysis and its clinical use in breast tumors].

Semiglazov VF, Semiglazov VV, Moiseenko FV, Bogdanov AA, Boĭtsov VV, Viaz'min SV, Gorab DN, Chubenko VA, Brezhnev NV, Luk'ianchikova VS, Dubina MV.

Vopr Onkol. 2013;59(1):25-9. Review. Russian. No abstract available.

PMID:
23805447
15.

Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis.

Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J.

Int J Gynecol Cancer. 2013 Jan;23(1):25-33. doi: 10.1097/IGC.0b013e3182788466. Review.

PMID:
23221605
16.

[Beyond staging, typing and grading. New challenges in breast cancer pathology].

Kreipe HH, Ahrens P, Christgen M, Lehmann U, Länger F.

Pathologe. 2010 Feb;31(1):54-9. doi: 10.1007/s00292-009-1244-y. Review. German.

PMID:
19949797
17.

Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring.

Heskamp S, van Laarhoven HW, Oyen WJ, van der Graaf WT, Boerman OC.

Curr Mol Med. 2013 Dec;13(10):1506-22. Review.

PMID:
24206139
18.

Hormone receptor expression in breast cancer: postanalytical issues.

Lee M, Lee CS, Tan PH.

J Clin Pathol. 2013 Jun;66(6):478-84. doi: 10.1136/jclinpath-2012-201148. Epub 2013 Mar 22. Review.

PMID:
23526546
19.

Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry.

Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, de las Mulas JM.

Vet Pathol. 2014 Jan;51(1):127-45. doi: 10.1177/0300985813509388. Epub 2013 Nov 13. Review.

PMID:
24227007
20.

Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.

Redfern A, Burslem K, Woodward N, Beith J, McCarthy N, De Boer R, Bell R.

Asia Pac J Clin Oncol. 2016 Mar;12 Suppl 1:19-31. doi: 10.1111/ajco.12492. Review.

PMID:
27001209

Supplemental Content

Support Center